PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26222F0276Jynarque tolvaptan - medication — Otsuka America Pharmaceutical, Inc

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Sep 30, 2022 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

262-Network Contract Office 22 (36C262)

Awarding office

Otsuka America Pharmaceutical, Inc

Recipient

Sep 30, 2022

PoP end

$137K

Obligated

$297K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Otsuka America Pharmaceutical, Inc — $90

Contract facts

Federal

Contract number36C26222F0276

Also listed as36C262-22-F-0276

Also listed as36F79720D0099-36C26222F0276

Agency262-Network Contract Office 22 (36C262)

Awarding office262-Network Contract Office 22 (36C262)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentOtsuka America Pharmaceutical, Inc

CAGE0ZHV7

UEIQKABLBMA8FT9

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79720D0099

Place of performanceROCKVILLE MD

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startApr 8, 2022

PoP end (current)Sep 30, 2022

Obligated$137K

Current value$297K

Potential value$297K

TOLVAPTAN (JYNARQUE) - MEDICATION FOR DIRECT PATIENT CARE (2) is a federal award for 262-Network Contract Office 22 (36C262) held by Otsuka America Pharmaceutical, Inc. Estimated value $297K ($137K obligated). Current period of performance ends Sep 30, 2022. Last award drew 1 bidder. Place of performance: ROCKVILLE MD.

TOLVAPTAN (JYNARQUE) - MEDICATION FOR DIRECT PATIENT CARE (2)

Recompete timing

Public

● Past PoP end (1421 days ago)

Current PoP ended Sep 30, 2022 (1421 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26222F0276?

36C26222F0276 (Jynarque tolvaptan - medication) is a 262-Network Contract Office 22 (36C262) award with a potential value of $297K, currently held by Otsuka America Pharmaceutical, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C262-22-F-0276?

36C262-22-F-0276 is the dashed form of PIID 36C26222F0276 (Jynarque tolvaptan - medication), held by Otsuka America Pharmaceutical, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26222F0276?

262-Network Contract Office 22 (36C262) awarded 36C26222F0276 to Otsuka America Pharmaceutical, Inc (potential $297K).

Who is the incumbent on 36C26222F0276?

Otsuka America Pharmaceutical, Inc is the incumbent. The current period of performance ends Sep 30, 2022.

When does Otsuka America Pharmaceutical, Inc’s 36C26222F0276 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 30, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jan 4, 2024 · refreshed monthly